AzTrials
AzTrials

CHARGE SyndromeNCT05764980

Neurovisual Function in CHARGE Syndrome

An observational study of CHARGE Syndrome, run by Fondazione Policlinico Universitario Agostino Gemelli IRCCS at 1 site in Italy.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The rationale of the study is to analyze visual function and correlate them with adaptive functions in patients with CHARGE syndrome in order to identify a pattern of specific indicators to enable better patient care Read more about this study

Who is it for?
Ages 0 to 90 years
Conditions the study is for
CHARGE Syndrome
What is being tested?
visual function evaluation
How many people
20 participants
Where
1 siteItaly
Study dates
15 Mar 2021to 1 Jan 2024
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 0 to 90 years
  • All sexes
  • Child, Adult, Older adult

Study population: Patients of all ages with molecularly confirmed CHARGE sidnrome

Who may be able to join

  • Patients with molecularly confirmed CHARGE syndrome.

Who cannot join

  • Patients with CHARGE syndrome that has not been molecularly confirmed

Trial locations and contacts

1 site in 1 country.

Giuseppe Zampino, medicine contact

00393392381870

giuseppe.zampino@unicatt.it

Italy1 site, 1 recruiting
  • Fondazione Policlinico Universitario A. Gemelli Irccs

    Roma, 00168

    GIUSEPPE ZAMPINO, MEDICINA

    Recruiting

Other trials in Italy

About this study

Official title: Assessment Study of Neurovisual Function in CHARGE Syndrome

The rationale of the study is to analyze visual function and correlate them with adaptive functions in patients with CHARGE syndrome in order to identify a pattern of specific indicators to enable better patient care

Read the detailed description

CHARGE syndrome is a malformative condition characterized by coloboma in about 70-95% of patients. This anatomical abnormality results in severe visual impairment that strongly affects the characterization of the disability profile.

Although the ocular anatomical deficits associated with the syndrome have been extensively described in the literature, coloboma being a major criterion for diagnosis, little is reported about the characteristics of visual function, such as acuity, visual field ocular motility, and other features.

Patients with CHARGE syndrome have multiple sensory deficif often accompanied by intellectual disability, which often makes the classical methods used in ophthalmologic evaluation inapplicable. According to the few studies in the literature, visual acuity in patients with CHARGE syndrome is often severely impaired with mean values below 20/60 (McMain et al 2008; Nishina et al 2012; Russell-Eggitt et al. 1990; Stromland et al. 2005; Tellier et al. 1998) However in opposition to the recurrent pessimistic findings resulting from ophthalmologic assessment in clinical practice, such patients present with good visual and adaptive abilities in daily life.

The rationale of the study is to analyze visual function and correlate them with adaptive functions in patients with CHARGE syndrome in order to identify a pattern of specific indicators to enable better patient care

Conditions
CHARGE Syndrome
Being tested
visual function evaluation
Keywords
CHARGE syndrome, Visual function
Medical subject headings
CHARGE Syndrome

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • visual function evaluationBehavioural

    visual function evaluation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. To demonstrate the correlation between severity of anatomical impairment and neurovisual ability.

    to detect aspects of visual function by studying ocular motility, visual acuity, contrast sensitivity, distance attention, and binocular visual field

    Measured: 4 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Mar 2023
  2. Study start15 Mar 2021
  3. Primary completion15 Mar 2023 (estimated)
  4. Study completion1 Jan 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
20 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05764980
Sponsor's protocol ID
3373
Status last verified
Mar 2023
First submitted
1 Mar 2023
Last updated
13 Mar 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of CHARGE Syndrome, run by Fondazione Policlinico Universitario Agostino Gemelli IRCCS at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 13 Mar 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Giuseppe Zampino, medicine (00393392381870, giuseppe.zampino@unicatt.it), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

To demonstrate the correlation between severity of anatomical impairment and neurovisual ability. (time frame: 4 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Mar 2023.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in